Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 22Carcinoma, Renal Cell 19HIV Infections 6Acquired Immunodeficiency Syndrome 6Sarcoma, Kaposi 5Leukemia 5Neoplasm Metastasis 4Lymphoma 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Triple Negative Breast Neoplasms 3Recurrence 3Neoplasms 3Kidney Neoplasms 3Hematologic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Mycosis Fungoides 2Multiple Myeloma 2Leukemia, Myeloid, Chronic-Phase 2Colorectal Neoplasms 2Breast Neoplasms 2Brain Neoplasms 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Tumor Virus Infections 1Thrombocythemia, Essential 1Solid Cancers 1

Interventions

Bevacizumab 7Paclitaxel 3vesencumab 2atezolizumab 2Immune Checkpoint Inhibitors 2Carboplatin 21-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one 2pertuzumab 1peginterferon alfa-2a 1parsatuzumab 1ovcon 35 1onartuzumab 1obinutuzumab 1ipatasertib 1emactuzumab 1Vitamin D 1Trastuzumab 1Rosiglitazone 1Pemetrexed 1Ipilimumab 1Interferon alpha-2 1HhAntag691 1Grape Seed Extract 1GDC-0623 1GDC-0152 1Docetaxel 1Cisplatin 1Capecitabine 12-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Cancers × Interferon alpha-2 × Clear all
NCT02174172 2020-05-12

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
158 enrolled

Solid Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡